Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 4

  • 755 clinical trials
  • 276 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Obesity122Type 2 diabetes mellitus85Overweight58Type 1 diabetes mellitus41Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Iron deficiency8+215

Clinical trials in Metabolism and nutrition disorders

755 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

755 clinical trials

Type 2 diabetes mellitus

Recruiting

Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Obesity

Recruiting

Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Obesity+1

Recruiting

Study comparing two forms of cagrilintide with placebo for weight loss in adults with overweight or obesity

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Type IIa hyperlipidaemia

Recruiting

Zodasiran for Adolescents With Homozygous Familial Hypercholesterolemia: A Phase 3 Study of Efficacy and Safety

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Zodasiran
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Type 1 diabetes mellitus

Recruiting

Safety and Pharmacokinetic Dose-Escalation Study of IMC-S118AI and Sodium Chloride in HLA‑A*02:01‑Positive Participants with Type 1 Diabetes

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Immunocore Limited

Arteriosclerosis coronary artery+2

Recruiting

Triple vs dual therapy with rosuvastatin, ezetimibe and bempedoic acid in patients with atherosclerotic heart disease and high cholesterol undergoing revascularisation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid
  • Sponsor:Medical University Of Graz

Overweight

Recruiting

Study of PF-08653945 Bioavailability After Subcutaneous Injection in the Thigh, Upper Arm, or Abdomen in Adults with Obesity

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Pfizer Inc.

Type 2 diabetes mellitus

Recruiting

Effect of dapagliflozin and semaglutide on heart insulin resistance in type 2 diabetes patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Ornithine transcarbamoylase deficiency

Recruiting

Long‑Term Safety Follow‑up of Ornithine Transcarbamylase Deficiency Patients Treated with ECUR‑506D and ECUR‑506A

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Adeno-Associated Virus Serotype Rh79 Containing The Human Otc Gene
  • Sponsor:Iecure Inc.

Osteoporotic fracture

Recruiting

Preventing Neuropathic Pain After Osteoporotic Vertebral Fracture with a 5% Lidocaine Patch in Adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lidocaine
  • Sponsor:University Hospital Of Clermont-Ferrand

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Obesity

Recruiting

Semaglutide for weight management in adults with obesity and binge‑eating: a study to identify who benefits

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Semaglutide
  • Sponsor:UZ Leuven

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide77 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsTirzepatide17 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsMetformin12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.